palonesetron

Phase 2Completed
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC

Conditions

Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC

Trial Timeline

Oct 27, 2009 → Dec 8, 2010

About palonesetron

palonesetron is a phase 2 stage product being developed by Eisai for Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC. The current trial status is completed. This product is registered under clinical trial identifier NCT01054456. Target conditions include Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01054456Phase 2Completed

Competing Products

20 competing products in Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC

See all competitors
ProductCompanyStageHype Score
R744 + R744Chugai PharmaceuticalPhase 3
77
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
77
R744 + Epoetin betaChugai PharmaceuticalPhase 3
77
R744 + R744Chugai PharmaceuticalPhase 3
77
R744 + R744Chugai PharmaceuticalPhase 3
77
R744Chugai PharmaceuticalPhase 3
77
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
41
FK949EAstellas PharmaPhase 1
33
roxadustatAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
ASP8825Astellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
ASP7991Astellas PharmaPhase 1
33
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
77
ATG-FAstellas PharmaApproved
85
CelecoxibAstellas PharmaPre-clinical
23
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
FK949EAstellas PharmaPhase 1
33